Anthracyclines clinical trials
A group of medicines. Daunorubicin (104 studies) and Aclarubicin (9 studies) are counted on their own pages; this page counts the studies that name Anthracyclines itself.
How each study uses Anthracyclines is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anthracyclines studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Medicines filed under Anthracyclines
As reviewed, so not every one. Each counts its studies on its own page, not here.
Studies by the year they started
8 studies that test it; most in 1996 (1)
| Year | Studies |
|---|---|
| 1996 | 1 |
| 2002 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 8
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · National Cancer Center, Korea (1) · Azza Shibl Sayed (1) · The Methodist Hospital Research Institute (1) · Shanghai Jiao Tong University School of Medicine (1) · Tao OUYANG (1) · Xijing Hospital (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1)
Often tested with
Tested in the same studies.
Paclitaxel (3) · Cyclophosphamide (3) · Albumin-Bound Paclitaxel (2) · Docetaxel (2) · Cytarabine (2) · Carboplatin (1) · Tislelizumab (1) · Capecitabine (1)
Studies
Open first, then newest update. How each study uses Anthracyclines is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Low Dose Induction for Pediatric Acute Myeloid Leukemia PatientsRecruitingNot applicableAzza Shibl SayedNCT07867600Written as Low dose Ara C/ anthracycline combined with GCSF
- Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease MarkerRecruitingPhase 2The Methodist Hospital Research InstituteNCT07060001Written as Anthracycline
- A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBCCompletedPhase 2Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNCT07827079Written as Nab paclitaxel/Carboplatin, anthracyclines,Tislelizumab
- Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary ChemotherapyStatus unknownPhase 3Tao OUYANGNCT01019616Written as paclitaxel/anthracycline
- Nab-paclitaxel Compared With Docetaxel Followed by Anthracyclines and Cyclophosphamide in the Neoadjuvant Breast CancerStatus unknownPhase 4Xijing HospitalNCT04182568Written as nab-paclitaxel followed by anthracycline and cyclophosphamide
- GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.Status unknownPhase 2Gruppo Italiano Malattie EMatologiche dell'AdultoNCT00439920Written as High-dose anthracycline
- Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast CancerTerminatedPhase 3Shanghai Jiao Tong University School of MedicineNCT00912444Written as Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide
- Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast CancerCompletedPhase 3National Cancer Center, KoreaNCT00352378Written as Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine
Given beside what is tested · 10 — Anthracyclines is usual care or a partner of the new treatment
- Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast CancerRecruitingPhase 2Shandong Cancer Hospital and InstituteNCT06802757Written as Anthracycline
- Study of SA+X in the Treatment of Newly Diagnosed AMLRecruitingPhase 2Ruijin HospitalNCT07548710Written as Anthracycline
- Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingPhase 2Fudan UniversityNCT06355037Written as Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
- Inosine Reverse Chemo Resistance in Triple Negative Breast CancerCompletedPhase 2Fudan UniversityNCT06355024Written as Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
- Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerCompletedPhase 3Bristol-Myers SquibbNCT04109066Written as anthracycline
- Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.CompletedPhase 3Novartis PharmaceuticalsNCT03379727Written as anthracycline ((daunorubicin or idarubicin): Induction Phase only
- Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AMLTerminatedPhase 3Kronos BioNCT05020665Written as Anthracycline
- Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)CompletedPhase 1Merck Sharp & Dohme LLCNCT02622074Written as Anthracycline (doxorubicin)
- HDM201 Added to CT in R/R or Newly Diagnosed AMLWithdrawnPhase 1/2Novartis PharmaceuticalsNCT03760445Written as anthracycline
- A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast CancerTerminatedPhase 1AstraZenecaNCT02561832Written as Anthracycline
As the comparator · 4 — what is tested is compared with Anthracyclines
- Organoid-based Functional Precision Therapy for Advanced Breast CancerRecruitingPhase 2Guangdong Provincial People's HospitalNCT06102824Written as Anthracycline
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingPhase 2UNICANCERNCT02299999Written as Anthracyclines
- Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast CancerCompletedPhase 2Cephalon, Inc.NCT00712881Written as Free doxorubicin hydrochloride
- Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and AdolescentsStatus unknownPhase 2/3University Hospital MuensterNCT00111345Written as Anthracyclines